Sanofi India's shares dipped close to their 52-week low at Rs 3,151 due to persistent poor financial results and challenging market conditions.

Sanofi India reported a 14% decrease in Q1 net profit for FY26, with earnings per share at Rs 44.55, due to a 12% decline in sales compared to the same period last year, totaling approximately Rs 472 crore.

Sanofi India has announced Rahul Bhatnagar as the new Chairman, taking over from Aditya Narayan starting April 30, 2026. Despite this news, shares of Sanofi India have dipped to ₹3434, falling slightly from their previous closing price. Trading volume on this day reached approximately ₹36.6 lakh.

Sanofi India announces the appointment of Rahul Bhatnagar as its new chairman, succeeding outgoing chairman, Anil Chawla. This change is effective immediately.

Sanofi India announces the appointment of Rahul Bhatnagar as its new chairman, replacing Aditya Narayan in this leadership role.

Sanofi India's Q1 earnings for 2026 reveal a decrease in both revenue and profit compared to the previous quarter.

Sanofi's Q1 profits increased by 36%, reaching INR 68 crores, with revenue growing by 33%. EBITDA climbed by 38.5%, boosting the margin to 38.7% compared to last year.

Sanofi India reports impressive double-digit growth in its insulin segment during Q4 FY26. Notably, the company's board undergoes significant changes as of April 30, 2026, with new directors and a reconstituted committee taking over.

Pharmaceutical company Sanofi has offloaded its tuberculosis treatment portfolio for approximately $2.1 million, resulting in a 10% increase in shares of Indian pharmaceutical firm Gujarat Themis. This deal marks a strategic shift for Sanofi in the global healthcare market.

Sanofi India secured a ₹52.1 crore GST refund, yet faces a rejection on a ₹11.6 crore claim and has decided to launch an appeal for the disputed amount.

Sanofi India will reveal its Q1 FY26 financial results on the 28th of April, 2026, following a board meeting approval. The trading window is currently closed from the 1st to the 30th of April in anticipation of these financial disclosures.

Sanofi India has declared a dividend of ₹48 per share with the ex-date set for April 22. Meanwhile, CIE Automotive, Schaeffler India, and Huhtamaki have also announced their dividends, but key dates differ among these companies.

Sanofi India announces its 70th Annual General Meeting for April 29, 2026, to be held via video conference in line with SEBI guidelines. The meeting will address key topics such as the presentation of audited financials, dividend decisions, appointments of new directors, and approval of related party transactions.

Sanofi India has proposed a dividend of ₹48 per share for the fiscal year 2025 (subject to AGM approval). This dividend is taxable and will be subject to TDS; therefore, shareholders are advised to update their PAN and bank details by April 15, 2026.